调节性免疫细胞在多发性骨髓瘤中的临床价值研究进展  

Research progress on clinical value of regulatory immune cells in multiple myeloma

作　　者：邹瑞基 邹忠晴 熊艳秋 饶进[2] 张丽[1] Ruiji Zou;Zhongqing Zou;Yanqiu Xiong;Jin Rao;Li Zhang(Department of Hematology,Institute of Hematology,West China Hospital,Sichuan University,Chengdu 610041,China;Department of Hematology,Affiliated Hospital of Chengdu University,Chengdu 610081,China)

机构地区：[1]四川大学华西医院血液内科血液病研究所,成都市610041 [2]成都大学附属医院血液内科

出　　处：《中国肿瘤临床》2022年第20期1033-1038,共6页Chinese Journal of Clinical Oncology

摘　　要：多发性骨髓瘤(multiple myeloma,MM)是骨髓浆细胞恶性增殖性疾病。尽管新药的出现显著改善了MM患者的预后,复发与耐药的问题仍有待解决,深入分析MM免疫微环境可能是潜在的突破口。免疫抑制微环境的形成是MM的突出特征,导致抗肿瘤免疫监视受损,恶性浆细胞发生免疫逃逸。调节性免疫细胞是免疫抑制微环境形成的重要因素,与MM的发病、进展和耐药密切相关。随着MM进入免疫治疗时代,调节性免疫细胞在MM诊断、治疗和预后中的价值逐渐被发现,其数量或比例变化可能有助于MM早期诊断和预后评估,并有望成为新的治疗靶点。本文将对调节性免疫细胞在MM临床诊治中的研究进展进行综述。Multiple myeloma(MM)is a malignant proliferative disease of plasma cells in the bone marrow.Despite new drugs significantly improving the prognosis of patients with MM,the problems of relapse and drug resistance remain unsolved.An in-depth understanding of the immune microenvironment of MM may be a potential breakthrough.The formation of an immunosuppressive microenvironment is a prominent feature of MM,which leads to impaired anti-tumor immune surveillance and immune escape of malignant plasma cells.Regulatory immune cells are important factors in the formation of immunosuppressive microenvironment and are closely related to the pathogenesis,progression,and drug resistance of MM.As we enter the era of immunotherapy,the importance of regulatory immune cells in the diagnosis,treatment,and prognosis of MM has been gradually discovered.Changes in their number or proportion may contribute to the early diagnosis and prognostic evaluation of MM.Regulatory immune cells may also become new therapeutic targets.Thus,this review focuses on the research progress of regulatory immune cells in diagnosing and treating MM.

关 键 词：多发性骨髓瘤 调节性免疫细胞 诊断 治疗 预后 

分 类 号：R733.3[医药卫生—肿瘤]